Roth Capital Downgrades bluebird bio Inc to Neutral

Brokerage firm Roth Capital Downgrades its rating on bluebird bio Inc(BLUE). The shares have been rated Neutral. Previously, the analysts had a Buy rating on the shares. The rating by Roth Capital was issued on Feb 6, 2017.

bluebird bio Inc (BLUE) shares turned negative on Tuesdays trading session with the shares closing down -4.2 points or -5.39% at a volume of 9,91,450. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $78.1. The peak price level was also seen at $78.1 while the days lowest was $72.8. Finally the shares closed at $73.7. The 52-week high of the shares is $79.7 while the 52-week low is $35.37. According to the latest information available, the market cap of the company is $2,749 M.

bluebird bio Inc(BLUE) last announced its earnings results on Aug 3, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $1.55M. Analysts had an estimated revenue of $2.20M. Earnings per share were $-1.59.

Several Insider Transactions has been reported to the SEC. On Feb 3, 2017, David Davidson (Chief Medical Officer) sold 2,000 shares at $74.03 per share price.Also, On Feb 2, 2017, James Mandell (director) sold 8,000 shares at $75.04 per share price.On Jan 31, 2017, Daniel Lynch (director) sold 1,000 shares at $70.09 per share price, according to the Form-4 filing with the securities and exchange commission.

bluebird bio Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Company’s products include Lenti-D LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy) the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.

Share this post

Leave a Reply